Cargando…

Are We Ready to Treat Diffuse Large B-cell and High-Grade Lymphoma According to Major Genetic Subtypes?

Diffuse Large B-Cell Lymphoma (DLBCL) is a clinically and biologically heterogeneous disease. The revised Classification of Lymphoproliferative diseases published in 2016 (WHO, 2016) refined the previous DLBLC subtypes and identified four categories: DLBCL not otherwise specified (NOS), other lympho...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chiappella, Annalisa, Crombie, Jennifer, Guidetti, Anna, Vitolo, Umberto, Armand, Philippe, Corradini, Paolo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2019
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6919463/ https://www.ncbi.nlm.nih.gov/pubmed/31942539 http://dx.doi.org/10.1097/HS9.0000000000000284

Ejemplares similares

Lenalidomide in Diffuse Large B-Cell Lymphomas
por: Chiappella, Annalisa, et al.
Publicado: (2012)

P1188: PERSONALIZED TREATMENT ACCORDING TO BIOLOGICAL PROFILE IMPROVES OUTCOME OF NEWLY DIAGNOSED PATIENTS AFFECTED BY DIFFUSE LARGE B-CELL LYMPHOMA: A REAL-LIFE EXPERIENCE
por: Guidetti, A., et al.
Publicado: (2022)

Diffuse Large B-Cell Lymphoma’s New Genomics: The Bridge and the Chasm
por: Crombie, Jennifer L., et al.
Publicado: (2020)

ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma
por: Nowakowski, Grzegorz S, et al.
Publicado: (2016)

A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients
por: Pellegrini, Cinzia, et al.
Publicado: (2016)

Intensified therapy in diffuse large B-cell lymphoma
por: Novo, Mattia, et al.
Publicado: (2017)

Editorial: Implementation of novel drugs and modern radiotherapy in the treatment of lymphoma patients
por: Levis, Mario, et al.
Publicado: (2023)

A three-gene signature based on MYC, BCL-2 and NFKBIA improves risk stratification in diffuse large B-cell lymphoma
por: Derenzini, Enrico, et al.
Publicado: (2020)

Phenotypic Composition of Commercial Anti-CD19 CAR T Cells Affects In Vivo Expansion and Disease Response in Patients with Large B-cell Lymphoma
por: Monfrini, Chiara, et al.
Publicado: (2022)

Large B-cell lymphomas
por: Vitolo, Umberto
Publicado: (2019)

Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome
por: Dodero, Anna, et al.
Publicado: (2021)

Characterization of GECPAR, a noncoding RNA that regulates the transcriptional program of diffuse large B-cell lymphoma
por: Napoli, Sara, et al.
Publicado: (2021)

Epigenomic evolution in diffuse large B-cell lymphomas
por: Pan, Heng, et al.
Publicado: (2015)

P1174: THE COMBINATION OF QUALITATIVE AND QUANTITATIVE METABOLIC PARAMETERS PREDICTS PROGRESSION-FREE SURVIVAL IN PATIENTS WITH LARGE B-CELL LYMPHOMAS (LBCL) TREATED WITH ANTI-CD19 CAR-T CELLS.
por: Dodero, A., et al.
Publicado: (2022)

S231: PRIMARY MEDIASTINAL B-CELL LYMPHOMA HAVE A SUPERIOR OUTCOME COMPARED TO DIFFUSE LARGE-B-CELL LYMPHOMA TREATED WITH AXICABTAGENE CILOLEUCEL IN THE CART-SIE REAL LIFE ITALIAN STUDY
por: Chiappella, Annalisa, et al.
Publicado: (2023)

Distribution of lymphoma subtypes in Ukraine according to the WHO 2016 classification
por: Kriachok, Iryna, et al.
Publicado: (2022)

Are We Ready to Implement Molecular Subtyping of Bladder Cancer in Clinical Practice? Part 2: Subtypes and Divergent Differentiation
por: Sanguedolce, Francesca, et al.
Publicado: (2022)

Are we ready?()
por: Pedrosa, C.
Publicado: (2020)

Upfront intensive chemo-immunotherapy with autograft in 199 adult mantle cell lymphoma patients: prolonged survival and cure potentiality at long term
por: Cortelazzo, Sergio, et al.
Publicado: (2021)

PB2113: FRONTMIND: A PHASE III, RANDOMIZED, DOUBLE-BLIND STUDY OF TAFASITAMAB + LENALIDOMIDE + R-CHOP VS R-CHOP ALONE FOR NEWLY DIAGNOSED HIGH-INTERMEDIATE AND HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA
por: Vitolo, U., et al.
Publicado: (2022)

Risk Factors and Incidence of Colorectal Cancer According to Major Molecular Subtypes
por: Wang, Liang, et al.
Publicado: (2020)

Follicular lymphoma grade 3B: low grade, high grade or should we skip the grade?
por: Mulvey, Erin, et al.
Publicado: (2023)

An overview of digital readiness in dentistry - are we ready?
por: Dickenson, Andrew, et al.
Publicado: (2022)

Are We Ready for Anything?
por: Neal-Boylan, Leslie
Publicado: (2020)

Are We Ready for Migrastatics?
por: Solomon, Jonathan, et al.
Publicado: (2021)

We are Ready for 2024!
Publicado: (2023)

Are we ready to include invasive cribriform and intraductal carcinoma into the prostate cancer grade grouping system?
por: Xiao, Guang-Qian, et al.
Publicado: (2020)

Microvascular characteristics of lower-grade diffuse gliomas: investigating vessel size imaging for differentiating grades and subtypes
por: Guo, Hong, et al.
Publicado: (2018)

Simplified algorithm for genetic subtyping in diffuse large B-cell lymphoma
por: Shen, Rong, et al.
Publicado: (2023)

QCD: are we ready for the LHC?
por: Frixione, Stefano
Publicado: (2006)

Are we ready for submental diversions?
por: Kundra, Pankaj, et al.
Publicado: (2016)

The World is Changing – Are We Ready?
Publicado: (2016)

Pandemic Influenza: Are We Ready?
por: Cinti, Sandro
Publicado: (2005)

Avian Influenza: Are We Ready?
por: Krau, Stephen D., et al.
Publicado: (2007)

Avian flu: Are we ready?
por: Aldhous, Peter, et al.
Publicado: (2005)

Are we ready for the new coronavirus?()
por: Peña-Otero, David, et al.
Publicado: (2020)

Personalised medicine: are we ready?
por: Louis, Renaud, et al.
Publicado: (2017)

Bioinformatics and the Metaverse: Are We Ready?
por: Taylor, Stephen, et al.
Publicado: (2022)

Treatment of Mantle Cell Lymphoma in the Frontline Setting: Are We Ready for a Risk-Adapted Approach?
por: Hammons, Lindsay, et al.
Publicado: (2022)

PB2132: COPANLISIB PLUS RITUXIMAB-BENDAMUSTINE FOR RELAPSED-REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: RECRUITMENT UPDATE ON AN ONGOING PHASE II TRIAL OF THE FONDAZIONE ITALIANA LINFOMI (FIL_COPA-RB)
por: Novo, M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_d1h7gebhstol7a5mj1hhk8suqq